Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 150 entries
Sorted by: Best Match Show Resources per page
Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy.

Radiology

Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA.
PMID: 1319075
Radiology. 1992 Jul;184(1):243-8. doi: 10.1148/radiology.184.1.1319075.

The ability of dynamic, gadolinium-enhanced magnetic resonance (MR) imaging to allow prediction of histologic responses to initial chemotherapy was evaluated in 20 patients with osteosarcoma (n = 12), Ewing sarcoma (n = 4), rhabdomyosarcoma (n = 3), or synovial...

Cite
Fletcher BD, Hanna SL, Fairclough DL, et al. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992;184(1):243-8doi: 10.1148/radiology.184.1.1319075.
Fletcher, B. D., Hanna, S. L., Fairclough, D. L., & Gronemeyer, S. A. (1992). Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology, 184(1), 243-8. https://doi.org/10.1148/radiology.184.1.1319075
Fletcher, B D, et al. "Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy." Radiology vol. 184,1 (1992): 243-8. doi: https://doi.org/10.1148/radiology.184.1.1319075
Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992 Jul;184(1):243-8. doi: 10.1148/radiology.184.1.1319075. PMID: 1319075.
Copy Download .nbib Format: NLM
Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital.

Cancer

Hutchison RE, Murphy SB, Fairclough DL, Shuster JJ, Sullivan MP, Link MP, Donaldson SS, Berard CW.
PMID: 2731117
Cancer. 1989 Jul 01;64(1):23-8. doi: 10.1002/1097-0142(19890701)64:1<23::aid-cncr2820640105>3.0.co;2-t.

The clinical relevance of a morphologic distinction between Burkitt's (B) and non-Burkitt's (NB) types of small non-cleaved cell (SNC) non-Hodgkin's lymphoma (NHL) has been controversial. Numerous attempts to discern an important clinical difference between the subtypes have failed to...

Cite
Hutchison RE, Murphy SB, Fairclough DL, et al. Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. Cancer. 1989;64(1):23-8doi: 10.1002/1097-0142(19890701)64:1<23::aid-cncr2820640105>3.0.co;2-t.
Hutchison, R. E., Murphy, S. B., Fairclough, D. L., Shuster, J. J., Sullivan, M. P., Link, M. P., Donaldson, S. S., & Berard, C. W. (1989). Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. Cancer, 64(1), 23-8. https://doi.org/10.1002/1097-0142(19890701)64:1<23::aid-cncr2820640105>3.0.co;2-t
Hutchison, R E, et al. "Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital." Cancer vol. 64,1 (1989): 23-8. doi: https://doi.org/10.1002/1097-0142(19890701)64:1<23::aid-cncr2820640105>3.0.co;2-t
Hutchison RE, Murphy SB, Fairclough DL, Shuster JJ, Sullivan MP, Link MP, Donaldson SS, Berard CW. Diffuse small noncleaved cell lymphoma in children, Burkitt's versus non-Burkitt's types. Results from the Pediatric Oncology Group and St. Jude Children's Research Hospital. Cancer. 1989 Jul 01;64(1):23-8. doi: 10.1002/1097-0142(19890701)64:1<23::aid-cncr2820640105>3.0.co;2-t. PMID: 2731117.
Copy Download .nbib Format: NLM
Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy.

International journal of radiation oncology, biology, physics

Arai Y, Kun LE, Brooks MT, Fairclough DL, Fontanesi J, Meyer WH, Hayes FA, Thompson E, Rao BN.
PMID: 1938559
Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1501-8. doi: 10.1016/0360-3016(91)90325-x.

Sixty children with localized osseous Ewing's sarcoma were treated between 1978 and 1988 with induction chemotherapy (cyclophosphamide, adriamycin), irradiation and/or surgery, and 10 months of maintenance chemotherapy (cyclophosphamide, adriamycin, dactinomycin, vincristine). Following induction chemotherapy, 43 patients received primary radiation...

Cite
Arai Y, Kun LE, Brooks MT, et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys. 1991;21(6):1501-8doi: 10.1016/0360-3016(91)90325-x.
Arai, Y., Kun, L. E., Brooks, M. T., Fairclough, D. L., Fontanesi, J., Meyer, W. H., Hayes, F. A., Thompson, E., & Rao, B. N. (1991). Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. International journal of radiation oncology, biology, physics, 21(6), 1501-8. https://doi.org/10.1016/0360-3016(91)90325-x
Arai, Y, et al. "Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy." International journal of radiation oncology, biology, physics vol. 21,6 (1991): 1501-8. doi: https://doi.org/10.1016/0360-3016(91)90325-x
Arai Y, Kun LE, Brooks MT, Fairclough DL, Fontanesi J, Meyer WH, Hayes FA, Thompson E, Rao BN. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1501-8. doi: 10.1016/0360-3016(91)90325-x. PMID: 1938559.
Copy Download .nbib Format: NLM
Subtle neuropsychological deficits in children with sickle cell disease.

The American journal of pediatric hematology/oncology

Wasserman AL, Wilimas JA, Fairclough DL, Mulhern RK, Wang W.
PMID: 2029072
Am J Pediatr Hematol Oncol. 1991;13(1):14-20. doi: 10.1097/00043426-199121000-00004.

Forty-three children and adolescents (8-16 years old) with sickle cell disease (SCD) and no overt neurologic dysfunction were evaluated with the Wechsler Intelligence Scale for Children-Revised (WISC-R), the Wide Range Achievement Test (WRAT), and an age-appropriate version of the...

Cite
Wasserman AL, Wilimas JA, Fairclough DL, et al. Subtle neuropsychological deficits in children with sickle cell disease. Am J Pediatr Hematol Oncol. 1991;13(1):14-20doi: 10.1097/00043426-199121000-00004.
Wasserman, A. L., Wilimas, J. A., Fairclough, D. L., Mulhern, R. K., & Wang, W. (1991). Subtle neuropsychological deficits in children with sickle cell disease. The American journal of pediatric hematology/oncology, 13(1), 14-20. https://doi.org/10.1097/00043426-199121000-00004
Wasserman, A L, et al. "Subtle neuropsychological deficits in children with sickle cell disease." The American journal of pediatric hematology/oncology vol. 13,1 (1991): 14-20. doi: https://doi.org/10.1097/00043426-199121000-00004
Wasserman AL, Wilimas JA, Fairclough DL, Mulhern RK, Wang W. Subtle neuropsychological deficits in children with sickle cell disease. Am J Pediatr Hematol Oncol. 1991;13(1):14-20. doi: 10.1097/00043426-199121000-00004. PMID: 2029072.
Copy Download .nbib Format: NLM
Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Kovnar EH, Kellie SJ, Horowitz ME, Sanford RA, Langston JW, Mulhern RK, Jenkins JJ, Douglass EC, Etcubanas EE, Fairclough DL.
PMID: 2153766
J Clin Oncol. 1990 Feb;8(2):330-6. doi: 10.1200/JCO.1990.8.2.330.

Medulloblastoma, pineoblastoma, and cerebral neuroblastoma are malignant embryonal tumors of the CNS that may demonstrate similar histologic features, a propensity for neuraxis dissemination and sensitivity to radiation therapy and, in certain cases, chemotherapy. To evaluate the activity of preirradiation...

Cite
Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol. 1990;8(2):330-6doi: 10.1200/JCO.1990.8.2.330.
Kovnar, E. H., Kellie, S. J., Horowitz, M. E., Sanford, R. A., Langston, J. W., Mulhern, R. K., Jenkins, J. J., Douglass, E. C., Etcubanas, E. E., & Fairclough, D. L. (1990). Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8(2), 330-6. https://doi.org/10.1200/JCO.1990.8.2.330
Kovnar, E H, et al. "Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 8,2 (1990): 330-6. doi: https://doi.org/10.1200/JCO.1990.8.2.330
Kovnar EH, Kellie SJ, Horowitz ME, Sanford RA, Langston JW, Mulhern RK, Jenkins JJ, Douglass EC, Etcubanas EE, Fairclough DL. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol. 1990 Feb;8(2):330-6. doi: 10.1200/JCO.1990.8.2.330. PMID: 2153766.
Copy Download .nbib Format: NLM
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors.

Cancer

Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME.
PMID: 7743483
Cancer. 1995 Jun 01;75(11):2762-7. doi: 10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>3.0.co;2-2.

BACKGROUND: Chemotherapy may be used to delay the need for cranial irradiation in infants and young children with malignant central nervous system (CNS) tumors. The polyfunctional alkylator thiotepa (TT) possesses significant in vitro and in vivo activity in many...

Cite
Razzouk BI, Heideman RL, Friedman HS, et al. A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 1995;75(11):2762-7doi: 10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>3.0.co;2-2.
Razzouk, B. I., Heideman, R. L., Friedman, H. S., Jenkins, J. J., Kun, L. E., Fairclough, D. L., & Horowitz, M. E. (1995). A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer, 75(11), 2762-7. https://doi.org/10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>3.0.co;2-2
Razzouk, B I, et al. "A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors." Cancer vol. 75,11 (1995): 2762-7. doi: https://doi.org/10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>3.0.co;2-2
Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME. A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 1995 Jun 01;75(11):2762-7. doi: 10.1002/1097-0142(19950601)75:11<2762::aid-cncr2820751121>3.0.co;2-2. PMID: 7743483.
Copy Download .nbib Format: NLM
Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Fairclough DL, Cella DF.
PMID: 8763800
Qual Life Res. 1996 Jun;5(3):321-9. doi: 10.1007/BF00433916.

The purpose of this investigation is to examine methods of scoring the FACT-G when there is non-response to individual questions. Using completed questionnaires from 350 patients, random and non-random missing responses where simulated. Seven methods of scoring the FACT-G...

Cite
Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5(3):321-9doi: 10.1007/BF00433916.
Fairclough, D. L., & Cella, D. F. (1996). Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 5(3), 321-9. https://doi.org/10.1007/BF00433916
Fairclough, D L, and Cella, D F. "Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions." Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation vol. 5,3 (1996): 321-9. doi: https://doi.org/10.1007/BF00433916
Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996 Jun;5(3):321-9. doi: 10.1007/BF00433916. PMID: 8763800.
Copy Download .nbib Format: NLM
Understanding the experience of pain in terminally ill patients.

Lancet (London, England)

Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ.
PMID: 11343734
Lancet. 2001 Apr 28;357(9265):1311-5. doi: 10.1016/S0140-6736(00)04515-3.

BACKGROUND: Terminally ill patients commonly experience substantial pain. Unresolved pain has been cited as evidence that end-of-life care is of poor quality. However, the data on which that conclusion is based are limited. We aimed to provide additional data...

Cite
Weiss SC, Emanuel LL, Fairclough DL, et al. Understanding the experience of pain in terminally ill patients. Lancet. 2001;357(9265):1311-5doi: 10.1016/S0140-6736(00)04515-3.
Weiss, S. C., Emanuel, L. L., Fairclough, D. L., & Emanuel, E. J. (2001). Understanding the experience of pain in terminally ill patients. Lancet (London, England), 357(9265), 1311-5. https://doi.org/10.1016/S0140-6736(00)04515-3
Weiss, S C, et al. "Understanding the experience of pain in terminally ill patients." Lancet (London, England) vol. 357,9265 (2001): 1311-5. doi: https://doi.org/10.1016/S0140-6736(00)04515-3
Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet. 2001 Apr 28;357(9265):1311-5. doi: 10.1016/S0140-6736(00)04515-3. PMID: 11343734.
Copy Download .nbib Format: NLM
Statistical analysis of quality of life with missing data in cancer clinical trials.

Statistics in medicine

Troxel AB, Fairclough DL, Curran D, Hahn EA.
PMID: 9549814
Stat Med. 1998 Mar 15-Apr 15;17(5):653-66. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m.

We summarize issues that arise when considering quality of life (QOL) data in cancer clinical trials, especially those related to missing data. We describe different types of missing data mechanisms, and discuss ways of assessing and testing missing data...

Cite
Troxel AB, Fairclough DL, Curran D, et al. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med. 1998;17(5):653-66doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m.
Troxel, A. B., Fairclough, D. L., Curran, D., & Hahn, E. A. (1998). Statistical analysis of quality of life with missing data in cancer clinical trials. Statistics in medicine, 17(5), 653-66. https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m
Troxel, A B, et al. "Statistical analysis of quality of life with missing data in cancer clinical trials." Statistics in medicine vol. 17,5 (1998): 653-66. doi: https://doi.org/10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m
Troxel AB, Fairclough DL, Curran D, Hahn EA. Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med. 1998 Mar 15-Apr 15;17(5):653-66. doi: 10.1002/(sici)1097-0258(19980315/15)17:5/7<653::aid-sim812>3.0.co;2-m. PMID: 9549814.
Copy Download .nbib Format: NLM
Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers.

JAMA

Emanuel EJ, Fairclough DL, Emanuel LL.
PMID: 11074775
JAMA. 2000 Nov 15;284(19):2460-8. doi: 10.1001/jama.284.19.2460.

CONTEXT: Euthanasia and physician-assisted suicide (PAS) are highly controversial issues. While there are studies of seriously ill patients' interest in euthanasia and PAS, there are no data on the attitudes and desires of terminally ill patients regarding these issues.OBJECTIVE:...

Cite
Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA. 2000;284(19):2460-8doi: 10.1001/jama.284.19.2460.
Emanuel, E. J., Fairclough, D. L., & Emanuel, L. L. (2000). Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA, 284(19), 2460-8. https://doi.org/10.1001/jama.284.19.2460
Emanuel, E J, et al. "Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers." JAMA vol. 284,19 (2000): 2460-8. doi: https://doi.org/10.1001/jama.284.19.2460
Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA. 2000 Nov 15;284(19):2460-8. doi: 10.1001/jama.284.19.2460. PMID: 11074775.
Copy Download .nbib Format: NLM
Planning analyses of quality-of-life studies: a case example with migraine prophylaxis.

Journal of biopharmaceutical statistics

Fairclough DL, Gagnon D, Papadopoulos G.
PMID: 15027499
J Biopharm Stat. 2004 Feb;14(1):31-51. doi: 10.1081/BIP-120028505.

Assessment of health-related quality of life (QOL) has become increasingly common in clinical trials. Because QOL has multiple dimensions and is assessed repeatedly over time, multiple comparisons and missing data must be addressed in the design and analysis of...

Cite
Fairclough DL, Gagnon D, Papadopoulos G. Planning analyses of quality-of-life studies: a case example with migraine prophylaxis. J Biopharm Stat. 2004;14(1):31-51doi: 10.1081/BIP-120028505.
Fairclough, D. L., Gagnon, D., & Papadopoulos, G. (2004). Planning analyses of quality-of-life studies: a case example with migraine prophylaxis. Journal of biopharmaceutical statistics, 14(1), 31-51. https://doi.org/10.1081/BIP-120028505
Fairclough, Diane L, et al. "Planning analyses of quality-of-life studies: a case example with migraine prophylaxis." Journal of biopharmaceutical statistics vol. 14,1 (2004): 31-51. doi: https://doi.org/10.1081/BIP-120028505
Fairclough DL, Gagnon D, Papadopoulos G. Planning analyses of quality-of-life studies: a case example with migraine prophylaxis. J Biopharm Stat. 2004 Feb;14(1):31-51. doi: 10.1081/BIP-120028505. PMID: 15027499.
Copy Download .nbib Format: NLM
The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ, Cella D.
PMID: 15058795
Qual Life Res. 2004 Feb;13(1):137-54. doi: 10.1023/B:QURE.0000015297.91158.01.

PURPOSE: This paper reports on the development and validation of two biologic response modifier (BRM) subscales for use with the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life (QOL) questionnaire.METHODS: Using the FACT-G as a base, 17 additional...

Cite
Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004;13(1):137-54doi: 10.1023/B:QURE.0000015297.91158.01.
Bacik, J., Mazumdar, M., Murphy, B. A., Fairclough, D. L., Eremenco, S., Mariani, T., Motzer, R. J., & Cella, D. (2004). The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 13(1), 137-54. https://doi.org/10.1023/B:QURE.0000015297.91158.01
Bacik, J, et al. "The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers." Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation vol. 13,1 (2004): 137-54. doi: https://doi.org/10.1023/B:QURE.0000015297.91158.01
Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ, Cella D. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res. 2004 Feb;13(1):137-54. doi: 10.1023/B:QURE.0000015297.91158.01. PMID: 15058795.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 150 entries